Lisata Therapeutics, Inc. Common Stock (LSTA)

Price$3.58

Value ScoreC

Growth ScoreF

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)47.39%

Price vs S&P 500 (4W)-1.14%

VGM Score36.06

Market Capitalization$29.60M

All Metrics

Book Value / Share (Quarterly)$1.20

P/TBV (Annual)1.10x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-78.84%

Cash Flow / Share (Quarterly)$-1.50

Price vs S&P 500 (YTD)63.80%

Gross Margin (TTM)9.52%

Net Profit Margin (TTM)-4478.24%

EPS (TTM)$-1.91

10-Day Avg Trading Volume0.20M

EPS Excl Extra (TTM)$-1.91

Revenue Growth (5Y)-58.81%

EPS (Annual)$-1.91

ROI (Annual)-111.65%

Gross Margin (Annual)9.56%

Net Profit Margin (5Y Avg)-2537.24%

Cash / Share (Quarterly)$1.43

Revenue Growth QoQ (YoY)-90.00%

ROA (Last FY)-93.47%

Revenue Growth TTM (YoY)-27.06%

EBITD / Share (TTM)$-2.08

ROE (5Y Avg)-66.74%

Operating Margin (TTM)-4674.71%

Cash Flow / Share (Annual)$-1.81

P/B Ratio2.71x

P/B Ratio (Quarterly)4.14x

Net Income / Employee (Annual)$-789,800

Net Interest Coverage (TTM)-1616.00x

ROA (TTM)-70.85%

EPS Incl Extra (Annual)$-1.91

Current Ratio (Annual)5.76x

Quick Ratio (Quarterly)3.94x

3-Month Avg Trading Volume0.16M

52-Week Price Return21.28%

Revenue / Employee (TTM)$8,100

Tangible BV / Share (Quarterly)$1.68

P/S Ratio (Annual)174.09x

Asset Turnover (Annual)0.01x

52-Week High$5.07

Operating Margin (5Y Avg)-2806.21%

EPS Excl Extra (Annual)$-1.91

CapEx CAGR (5Y)6.96%

Tangible BV CAGR (5Y)5.57%

26-Week Price Return63.32%

Quick Ratio (Annual)5.20x

13-Week Price Return-26.30%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.23x

Enterprise Value$16.54M

Revenue / Share Growth (5Y)-83.48%

Asset Turnover (TTM)0.01x

Book Value / Share Growth (5Y)-36.18%

Revenue / Employee (Annual)$8,100

Inventory Turnover (Annual)0.82x

Pretax Margin (Annual)-10322.35%

Cash / Share (Annual)$1.81

3-Month Return Std Dev78.41%

Gross Margin (5Y Avg)11.85%

Net Income / Employee (TTM)$-789,800

ROE (Last FY)-111.65%

Net Interest Coverage (Annual)-71.89x

EPS Basic Excl Extra (Annual)$-1.91

P/FCF (TTM)6.59x

Receivables Turnover (TTM)0.38x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.91

Receivables Turnover (Annual)0.38x

ROI (TTM)-84.39%

P/S Ratio (TTM)174.09x

Pretax Margin (5Y Avg)-2682.23%

Revenue / Share (Annual)$0.02

Tangible BV / Share (Annual)$1.68

Price vs S&P 500 (52W)-6.93%

Year-to-Date Return74.73%

5-Day Price Return3.50%

EPS Normalized (Annual)$-1.91

ROA (5Y Avg)-58.26%

Net Profit Margin (Annual)-9756.47%

Month-to-Date Return4.17%

Cash Flow / Share (TTM)$-2.66

EBITD / Share (Annual)$-2.08

Operating Margin (Annual)-10711.18%

LT Debt / Equity (Annual)0.55x

ROI (5Y Avg)-66.74%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.91

P/TBV (Quarterly)1.10x

P/B Ratio (Annual)1.10x

Inventory Turnover (TTM)1.23x

Pretax Margin (TTM)-4478.24%

Book Value / Share (Annual)$1.68

Price vs S&P 500 (13W)-36.05%

Beta0.81x

P/FCF (Annual)29.30x

Revenue / Share (TTM)$0.02

ROE (TTM)-84.39%

52-Week Low$1.81

vGradeC

gGradeF

mGradeC

vgmGradeD

Show chart for

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.11

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
LSTALisata Therapeutics, Inc. Common Stock	C	F	C	$3.58
LLYEli Lilly & Co.	D	B	B	$1082.20
JNJJohnson & Johnson	C	C	C	$223.51
ABBVABBVIE INC.	D	C	C	$212.93
MRKMerck & Co., Inc.	C	C	C	$115.17
NVSNovartis AG	C	C	C	$145.68
AZNAstraZeneca PLC	D	B	C	$179.71
NVONovo-Nordisk A/S	B	B	C	$44.07
ABTAbbott Laboratories	C	C	D	$87.78
PFEPfizer Inc.	B	C	C	$25.63
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$34.64

About

Lisata Therapeutics is a clinical-stage biopharmaceutical company developing novel therapies for solid tumors. Its lead candidate, certepetide, is designed to activate a proprietary uptake pathway that enhances the ability of co-administered anti-cancer drugs to penetrate and target solid tumors more effectively.